NO944273L - tat-avledede transportpolypeptider - Google Patents
tat-avledede transportpolypeptiderInfo
- Publication number
- NO944273L NO944273L NO944273A NO944273A NO944273L NO 944273 L NO944273 L NO 944273L NO 944273 A NO944273 A NO 944273A NO 944273 A NO944273 A NO 944273A NO 944273 L NO944273 L NO 944273L
- Authority
- NO
- Norway
- Prior art keywords
- tat
- transport polypeptides
- polypeptides
- absence
- amino acids
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 101710149951 Protein Tat Proteins 0.000 abstract 5
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 235000018417 cysteine Nutrition 0.000 abstract 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93437592A | 1992-08-21 | 1992-08-21 | |
PCT/US1993/007833 WO1994004686A1 (en) | 1992-08-21 | 1993-08-19 | Tat-derived transport polypeptides |
Publications (3)
Publication Number | Publication Date |
---|---|
NO944273D0 NO944273D0 (no) | 1994-11-09 |
NO944273L true NO944273L (no) | 1995-02-17 |
NO316761B1 NO316761B1 (no) | 2004-05-03 |
Family
ID=25465458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19944273A NO316761B1 (no) | 1992-08-21 | 1994-11-09 | tat-avledede transportpolypeptider |
Country Status (14)
Country | Link |
---|---|
EP (3) | EP2000536A3 (no) |
JP (2) | JP2702285B2 (no) |
KR (1) | KR0153027B1 (no) |
AT (1) | ATE173016T1 (no) |
AU (1) | AU667244B2 (no) |
CA (1) | CA2135642C (no) |
DE (2) | DE656950T1 (no) |
DK (1) | DK0656950T3 (no) |
ES (1) | ES2123062T3 (no) |
FI (1) | FI120495B (no) |
HK (1) | HK1012678A1 (no) |
NO (1) | NO316761B1 (no) |
NZ (1) | NZ255831A (no) |
WO (1) | WO1994004686A1 (no) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219990A (en) * | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
US5955593A (en) * | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
US6623938B2 (en) * | 1997-01-21 | 2003-09-23 | Human Genome Sciences, Inc. | I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis |
ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
DE69819150T3 (de) | 1997-06-06 | 2007-12-20 | Dynavax Technologies Corp., San Diego | Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
AU755564B2 (en) * | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
US7306784B2 (en) | 1998-06-20 | 2007-12-11 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
AU762006B2 (en) * | 1998-12-24 | 2003-06-19 | Ucb | Peptidic product, process and composition |
DE19916224C1 (de) | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
WO2001015511A2 (en) * | 1999-09-01 | 2001-03-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
CA2396149A1 (en) * | 2000-01-07 | 2001-07-12 | Artemis Pharmaceuticals Gmbh | Transduction of recombinases for inducible gene targeting |
DK2364734T3 (en) * | 2000-07-21 | 2017-10-30 | Revance Therapeutics Inc | Biological multicomponent transport systems |
KR100379577B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법 |
KR100379578B1 (ko) * | 2000-07-26 | 2003-04-08 | 최수영 | 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법 |
EP2149604A1 (en) | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
CA2437983C (en) | 2001-02-16 | 2011-10-25 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
JP4130955B2 (ja) * | 2001-06-05 | 2008-08-13 | 真寛 平岡 | 有酸素条件下の細胞内でタンパク質を不安定化させるポリペプチドとそれをコードするdna |
KR100495138B1 (ko) * | 2001-07-31 | 2005-06-14 | 학교법인 한림대학교 | 식물세포 투과 도메인-화물분자 복합체 |
WO2003025220A2 (en) | 2001-09-18 | 2003-03-27 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
AU2002356824A1 (en) * | 2001-10-19 | 2003-05-06 | The Scripps Research Institute | Novel methods for introducing molecules into cells and vectors and compositions for use in such methods |
JP2005525096A (ja) | 2002-01-09 | 2005-08-25 | ユニバーシティ オブ ローザンヌ | Jnkシグナル伝達経路の細胞浸透性ペプチドインヒビター |
US7026166B2 (en) | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
WO2003086470A2 (en) * | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
EP1354953A1 (en) * | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
US7459424B2 (en) | 2002-04-22 | 2008-12-02 | The Borad Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase C γ for pain management |
KR100472939B1 (ko) * | 2002-05-24 | 2005-03-18 | 학교법인 한림대학교 | 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도 |
AU2003254066B2 (en) | 2002-07-19 | 2009-08-27 | The Regents Of The University Of California | Dendrimers as molecular translocators |
KR100472938B1 (ko) * | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
JPWO2005035562A1 (ja) * | 2003-10-07 | 2007-11-22 | 伸弥 山中 | 新規な細胞増殖促進剤 |
US7700737B2 (en) | 2003-12-05 | 2010-04-20 | Multimmune Gmbh | Therapeutic and diagnostic anti-Hsp70 antibodies |
US8974774B2 (en) | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
JP4474264B2 (ja) * | 2004-08-20 | 2010-06-02 | 生寶生物科技股▲ふん▼有限公司 | 子宮頸癌抑制の融合蛋白 |
WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
JP4596391B2 (ja) | 2005-02-10 | 2010-12-08 | 国立大学法人大阪大学 | 細胞透過性ペプチド |
EP1988167B1 (fr) * | 2005-02-17 | 2020-04-01 | Sorbonne Universite | Peptides inhibiteurs intracellulaires |
NZ560799A (en) | 2005-03-03 | 2009-10-30 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
ZA200707352B (en) | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1861417B1 (en) | 2005-03-10 | 2013-05-15 | BioNTech AG | Dimeric or multimeric microproteins |
US7973084B2 (en) | 2005-04-28 | 2011-07-05 | Postech Academy-Industrial Foundation | Molecular transporters based on alditol or inositol and processes for the preparation thereof |
KR100699279B1 (ko) * | 2005-04-28 | 2007-03-23 | 학교법인 포항공과대학교 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
IN2014DN06624A (no) | 2005-10-18 | 2015-07-10 | Univ Colorado | |
US7517959B2 (en) | 2005-11-11 | 2009-04-14 | Walter And Eliza Hall Institute Of Medical Research | SOCS3 proteins |
PT2099826E (pt) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
CA2680914C (en) | 2007-03-13 | 2019-06-18 | University Of Zurich | Monoclonal human tumor-specific antibody |
CN101688228B (zh) | 2007-03-13 | 2014-12-24 | 国家犾太健康中心 | 抗体产生的方法 |
JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
KR101722038B1 (ko) | 2007-07-26 | 2017-04-03 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
EP2527369A3 (en) | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
US7935816B2 (en) | 2007-10-25 | 2011-05-03 | Gene Tools, Llc | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo |
WO2009107766A1 (ja) | 2008-02-28 | 2009-09-03 | 東レ株式会社 | 経鼻投与用医薬組成物 |
CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
CN102083970B (zh) | 2008-07-21 | 2014-10-22 | 泰加生物工艺学公司 | 分化无核细胞及其制备方法 |
CA2735710A1 (en) | 2008-08-04 | 2010-02-11 | Glen N. Barber | Sting (stimulator of interferon genes), a regulator of innate immune responses |
DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
ES2546304T3 (es) | 2009-05-20 | 2015-09-22 | Toray Industries, Inc. | Péptidos permeables para la membrana celular |
EP2488210A4 (en) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
CN105457016B (zh) | 2010-09-22 | 2022-06-24 | 科罗拉多大学董事会 | Smad7的治疗应用 |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
JP5828909B2 (ja) | 2011-01-10 | 2015-12-09 | シーティー アトランティック リミテッド | 腫瘍関連抗原結合抗体を含む併用療法 |
CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
EP2714742A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
EP2714743A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
US20150030602A1 (en) | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
SI2797952T1 (sl) | 2011-12-28 | 2019-07-31 | Immunoqure Ag | Postopek za pripravo monoklonskih avto-protiteles z želeno specifičnostjo |
US9789135B2 (en) | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10456448B2 (en) | 2013-03-08 | 2019-10-29 | The Regents Of The University Of Colorado, A Body Corporate | PTD-SMAD7 therapeutics |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US10981961B2 (en) | 2013-03-11 | 2021-04-20 | University Of Florida Research Foundation, Incorporated | Delivery of card protein as therapy for occular inflammation |
PL3013353T3 (pl) * | 2013-06-26 | 2021-09-20 | Xigen Inflammation Ltd. | Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2015001013A2 (en) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
US11053291B2 (en) | 2014-02-19 | 2021-07-06 | University Of Florida Research Foundation, Incorporated | Delivery of Nrf2 as therapy for protection against reactive oxygen species |
EP3116898B1 (en) | 2014-03-11 | 2022-01-26 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
JP6468722B2 (ja) * | 2014-04-30 | 2019-02-13 | 日本信号株式会社 | 物体検出装置 |
US11292838B2 (en) | 2015-06-01 | 2022-04-05 | Medigene Immunotherapies Gmbh | Method for generating antibodies against T cell receptor |
WO2016193299A1 (en) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
KR20180020202A (ko) | 2015-06-01 | 2018-02-27 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 특이적 항체 |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
EP3309178A4 (en) | 2015-06-11 | 2019-05-08 | Keio University | FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR |
KR20200100858A (ko) | 2015-12-23 | 2020-08-26 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 조성물 |
KR20190092472A (ko) | 2016-12-02 | 2019-08-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 나노입자 제제 |
PT3554553T (pt) | 2016-12-19 | 2022-08-04 | Sarepta Therapeutics Inc | Conjugados oligoméricos de salto de exão para a distrofia muscular |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
JP7489319B2 (ja) | 2018-09-26 | 2024-05-23 | 株式会社カネカ | 細胞膜透過性ペプチド |
WO2022154079A1 (ja) * | 2021-01-18 | 2022-07-21 | 国立研究開発法人産業技術総合研究所 | タンパク質を動物細胞に導入する方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505102A (ja) * | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 真核細胞の中に分子を配達する方法 |
US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
-
1993
- 1993-08-19 ES ES93920231T patent/ES2123062T3/es not_active Expired - Lifetime
- 1993-08-19 WO PCT/US1993/007833 patent/WO1994004686A1/en active IP Right Grant
- 1993-08-19 DE DE0656950T patent/DE656950T1/de active Pending
- 1993-08-19 DE DE69321962T patent/DE69321962T2/de not_active Expired - Lifetime
- 1993-08-19 CA CA002135642A patent/CA2135642C/en not_active Expired - Lifetime
- 1993-08-19 NZ NZ255831A patent/NZ255831A/en not_active IP Right Cessation
- 1993-08-19 DK DK93920231T patent/DK0656950T3/da active
- 1993-08-19 EP EP08004968A patent/EP2000536A3/en not_active Withdrawn
- 1993-08-19 EP EP98105625A patent/EP0903408A3/en not_active Ceased
- 1993-08-19 AT AT93920231T patent/ATE173016T1/de active
- 1993-08-19 AU AU50832/93A patent/AU667244B2/en not_active Expired
- 1993-08-19 EP EP93920231A patent/EP0656950B1/en not_active Expired - Lifetime
- 1993-08-19 JP JP6506542A patent/JP2702285B2/ja not_active Expired - Lifetime
-
1994
- 1994-11-08 FI FI945248A patent/FI120495B/fi not_active IP Right Cessation
- 1994-11-09 NO NO19944273A patent/NO316761B1/no not_active IP Right Cessation
- 1994-12-28 KR KR1019940704779A patent/KR0153027B1/ko not_active IP Right Cessation
-
1997
- 1997-04-14 JP JP9096264A patent/JP2869396B2/ja not_active Expired - Lifetime
-
1998
- 1998-12-17 HK HK98113962A patent/HK1012678A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2000536A3 (en) | 2010-06-30 |
CA2135642A1 (en) | 1994-03-03 |
AU5083293A (en) | 1994-03-15 |
DE656950T1 (de) | 1996-03-14 |
DE69321962D1 (de) | 1998-12-10 |
CA2135642C (en) | 1999-12-14 |
NZ255831A (en) | 1997-04-24 |
JP2702285B2 (ja) | 1998-01-21 |
EP0903408A2 (en) | 1999-03-24 |
AU667244B2 (en) | 1996-03-14 |
NO316761B1 (no) | 2004-05-03 |
DK0656950T3 (da) | 1999-07-19 |
EP2000536A2 (en) | 2008-12-10 |
FI120495B (fi) | 2009-11-13 |
ATE173016T1 (de) | 1998-11-15 |
ES2123062T3 (es) | 1999-01-01 |
KR0153027B1 (en) | 1998-10-15 |
JP2869396B2 (ja) | 1999-03-10 |
DE69321962T2 (de) | 1999-07-01 |
NO944273D0 (no) | 1994-11-09 |
EP0656950A1 (en) | 1995-06-14 |
FI945248A0 (fi) | 1994-11-08 |
WO1994004686A1 (en) | 1994-03-03 |
EP0903408A3 (en) | 2005-11-02 |
FI945248A (fi) | 1995-01-05 |
JPH1033186A (ja) | 1998-02-10 |
JPH07503617A (ja) | 1995-04-20 |
HK1012678A1 (en) | 1999-08-06 |
EP0656950B1 (en) | 1998-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0656950T3 (da) | TAT-afledte transportpolypeptider | |
GB9720054D0 (en) | Biological products | |
IL128727A0 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
PT749317E (pt) | Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade | |
DE69033040D1 (de) | Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF) | |
FI913637A0 (fi) | Foer epitelceller specifik dna kodande vaextfaktor. | |
MX9207334A (es) | Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene | |
DE69805772D1 (de) | Stabilisierte mischung auf fibrinogenbasis | |
ATE68976T1 (de) | Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. | |
NO20012017D0 (no) | Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose | |
ATE199377T1 (de) | Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung | |
ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
DE60042220D1 (de) | Verwendung vom transportergen oatp-c zur screening von testsubstanzen | |
DE3273606D1 (en) | Process for the purification or concentration of biologically active proteins, and appropriate means therefor | |
ATE214708T1 (de) | Kationische mittel zur transfektion von nukleinsäuren | |
ITRM920506A1 (it) | Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi. | |
ATE143974T1 (de) | Peptide des hiv-gag proteins, ihre herstellung und verwendung | |
ATE205538T1 (de) | Genregulatorische sequenzen von cd4, welche spezifisch in reifen t-zellen exprimiert werden | |
DE69533545D1 (de) | Faltende proteine | |
許奎晶 | Small GTP-binding Proteins | |
Perraudin et al. | Disulfide content of reduced hen egg white and human milk lysozymes during the folding process | |
KR950023648A (ko) | 생물학적 활성을 나타내는 폴리펩티드 | |
MIRZA | jllafiter of $ l| ilofl (oplip | |
PT97820A (pt) | Processo de obtencao de proteina map2-quinases, de microorganismos e linhas de celulas compreendendo moleculas recombinantes de map2-quinase e de detencao da presenca de actividade de factores celulares | |
TH23717A (th) | ธรอมโบพอยเอติน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |